Silent risk of osteoporosis in men with prostate cancer

Men being treated for prostate cancer using hormone therapy maybe under-recognized for their risk of developing osteoporosis, according to a new study. Researchers writing in the January 15, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society, say few patients get tested for osteoporosis during treatment. Moreover, even men with other risk factors for osteoporosis, such as smoking or receiving the hormone treatment for a long time, are still unlikely to receive prevention or treatment.


Osteoporosis is a disease characterized by brittle, easily fractured bones that is associated with significant morbidity, mortality, and healthcare cost. It is caused by dysregulation of the hormone-regulated bone remodeling system that leads to a loss of bone mineral density. Risk factors for male osteoporosis include age-associated hormone changes, alcoholism, smoking, some medications, including those used in the treatment of prostate cancer.

Osteoporosis can be prevented and even treated using a wide range of therapies. Common prevention measures include calcium and vitamin D supplements, regular exercise. Screening test such as the dual-energy X-ray absorptiometry (DXA) scan is also available. But, even now, there is no established national consensus guiding doctors of when and what to prescribe. Treatment strategies include bisphosphonates, which have been shown to prevent further bone loss, but it is inconvenient, sometimes expensive, and may cause serious side effects. To find out how clinicians were managing osteoporosis risk in the U.S. in year 2003 and identify factors that might predict who gets treated, Tawee Tanvetyanon, M.D. from Loyola University Chicago Stritch School of Medicine reviewed the sampled records of 184 prostate cancer patients who received androgen deprivation therapy (ADT), which is known to raise the risk of osteoporosis.

Dr. Tanvetyanon found that “the majority of patients undergoing ADT did not receive osteoporosis prevention or treatment,” even when they reported other risk factors, as well. Only about one in seven (14.7 percent) eligible patients received any sort of osteoporosis management. Fewer than one in ten (8.7 percent) received at least one DXA scan within three years, and only one in twenty (4.9 percent) was prescribed a bisphosphonate. The only factor that predicted clinical management of osteoporosis risk and disease was the presence of bony metastases (prostate cancers that had spread to the bones). Analysis also showed that primary care physicians were the most aggressive at managing osteoporosis while cancer specialists were the least.

Media Contact

David Greenberg EurekAlert!

All latest news from the category: Health and Medicine

This subject area encompasses research and studies in the field of human medicine.

Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.

Back to home

Comments (0)

Write a comment

Newest articles

Lighting up the future

New multidisciplinary research from the University of St Andrews could lead to more efficient televisions, computer screens and lighting. Researchers at the Organic Semiconductor Centre in the School of Physics and…

Researchers crack sugarcane’s complex genetic code

Sweet success: Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance in plants….

Evolution of the most powerful ocean current on Earth

The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….

Partners & Sponsors